Reviewing Vertex Pharmaceuticals (NASDAQ:VRTX) and Caribou Biosciences (NASDAQ:CRBU)

Caribou Biosciences (NASDAQ:CRBU) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent recommendations for Caribou Biosciences and Vertex Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caribou Biosciences	1	3	3	1	2.50
Vertex Pharmaceuticals	0	2	20	1	2.96

Caribou Biosciences currently has a consensus price target of $5.50, suggesting a potential upside of 790.83%. Vertex Pharmaceuticals has a consensus price target of $575.13, suggesting a potential upside of 13.74%. Given Caribou Biosciences’ higher possible upside, equities analysts clearly believe Caribou Biosciences is more favorable than Vertex Pharmaceuticals.

Profitability

This table compares Caribou Biosciences and Vertex Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Caribou Biosciences	-1,030.42%	-89.11%	-62.47%
Vertex Pharmaceuticals	35.00%	23.09%	16.72%

Valuation and Earnings

This table compares Caribou Biosciences and Vertex Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caribou Biosciences	$11.16 million	5.93	-$148.12 million	($1.08)	-0.57
Vertex Pharmaceuticals	$12.00 billion	10.69	$3.95 billion	$17.18	29.43

Vertex Pharmaceuticals has higher revenue and earnings than Caribou Biosciences. Caribou Biosciences is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

77.5% of Caribou Biosciences shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 8.5% of Caribou Biosciences shares are owned by insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Caribou Biosciences has a beta of 2.31, indicating that its share price is 131% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500.

Summary

Vertex Pharmaceuticals beats Caribou Biosciences on 11 of the 14 factors compared between the two stocks.

About Caribou Biosciences

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.